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Abstract
Aim: To evaluate daily blood pressure monitoring (DBPM) data changes in patients with essential
arterial hypertension (EAH) under the influence of pharmacogenetically determined treatment depending
on genes polymorphisms of angiotensin-converting enzyme (ACE, I/D), angiotensin II first type receptor
(AGTR1, А1166С), endothelial NO-synthase (eNOS, T894G), peroxisome proliferators-activated recep-
tor-γ2 (PPAR-γ2, Pro12Ala), β1-adrenergic receptor (ADRB1, Arg389Gly).
Material and Methods: 249 patients with EAH І-ІІІ stages (48.2% – women, 51.8% – men, mean 
ages 50.5±10.4 years) and 50 practically healthy persons were observed. Alleles of polymorphic locus 
were assessed by polymerase chain reaction (PCR) based method. DBPM was performed according to 
standard protocol. 
Patients were split by genotypes and treatment type into 6 groups: 
• 1st group: I-allele of ACE gene carriers (n=60) took Hydrochlorothiazide (HCTZ) and angio-
tensin II receptor blocker (ARB II); 
• 2nd group: I/D-genotype carriers (n=34) took HCTZ+β1-adrenobloker (β1-АB); 
• 3rd group: I/D-genotype carriers (n=50) took HCTZ+ACE-inhibitor (ACEI); 
• 4th group: DD-genotype carriers (n=15) took calcium channels bloker (CCB)+ ARB II; 
• 5th group: DD-genotype carriers (n=15) took CCB+β1-АB; 
• 6th group: DD-genotype carriers (n=27) took CCB+ACEI. 
Treatment efficacy was analyzed according to European Guidelines (2007). 
Results: Pharmacogenetically determined treatment of EAH patients during 9-12 months caused 
daily, day, and night blood pressure (BP) decrease below the “threshold” level in 154 (76.6%)
patients. That did not significantly differ from the frequency of “target” office BP achievement: 149 
(74.1%). The number of patients with normal BP daily profile “dipper” increased reliably by 10.1% 
(р<0.001), with “non-dipper” and “night-peaker” patients amount diminishing (р<0.05). Long-
term combined therapy caused achievement of “target” average daily BP24 (DBPM) depending on 
types of treatment combination: after HCTZ+ARB ІІ – in 55 (91.7%) patients; after HCTZ+β1-AB 
– in 25 (73.5%) persons; after HCTZ+ACEI – in 33 (66.0%) patients; after CCB+ARB II – in 11 
(73.3%) persons, without a reliable difference between genotypes; after CCB+β1-AB – in 11 (73.3%) 
patients (easier in Ala-allele carriers of PPAR-γ2 gene, р=0.002); after CCB+ACEI – in 19 (70.4%) 
patients (easier in AlaAla-genotype carriers of PPAR-γ2 gene, р=0.007). 
Conclusions: Prescription of HCTZ+ARB II drugs combination is more effective in treatment of 
EAH І-allele carriers of ACE gene patients than HCTZ+β1-АB or HCTZ+ACEI – 91.7% vs 66.0 or 
73.5%, accordingly (р<0.001); for DD-genotype carrier hypertensive patients the combination of 
CCB+ARB II and CCB+β1-АB is more effective than CCB+ACEI – 73.3% vs 70.4%, accordingly.
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INTRODUCTION
Arterial Hypertension (AH) treatment is one of 
the most actual problems of modern medical sci-
ence. Far beyond the limits of cardiologic pathol-
ogy, AH became a topical problem in medical prac-
tice of internal disease doctors and general practi-
tioners. In Ukraine, almost 10 million people have a 
high blood pressure (BP). Epidemiology research of 
the National Ukrainian Scientific Centre “Institute 
of cardiology named after M.D. Strazhesko” indi-
cates that AH is diagnosed in 35% of adult Ukrain-
ian population [Sirenko Yu. et al., 2006]. Last years 
the pandemic character of AH was mostly predefined 
by the life style of population. However, the influ-
ence of environmental factors could be realized in 
connection with the individual human genotype. 
Despite the numerous studies devoted to the discov-
ery of potential genes-candidates of AH or ischemic 
heart disease (IHD), accumulated information on 
their genetic origin is not yet sufficient [Tiret L. et al., 
1998; Cadman P., O’Connor D., 2003; Mooser V. et al.,
2003; Ioannidis J., 2009]. A several tens of genes, 
which encode the synthesis of certain enzymes in 
the conditions of RAAS or eNO-systems activating, 
are known nowadays. They regulate vessels tone, 
endothelium function, salt, hydrocarbon and lipids 
metabolisms, etc. [Headley A. et al., 2007; Hiltunen
T. et al., 2006; Jankowska K. et al., 2007; Karlsson
J. et al., 2004]. However, in Ukraine likewise other 
countries all over the world, similar studies were 
limited [Ohmichi N. et al., 1997; Celuyko V., Peleck-
aya O., 2008; Dzyak G.V., Kolesnyk T., 2008; Ioan-
nidis J., 2009; Parkhomenko A.N. et al., 2008; Syd-
orchuk L.,2008; . Sydorchuk L. et al., 2008; 2009; 
2010; Tykhonova S., Litovkin K., 2008], whereas AH 
related morbidity in population is still high and effi-
cacy of treatment does not exceed 18.7% among the 
urban and 8.0% among rural population of Ukraine 
[Sirenko Yu. et al., 2006]. Low efficacy of existing 
methods of AH treatment, insufficiently personalized
drugs sensitivity, drugs side-effects compelled an 
urgent necessity to improve and develop new therapy
approaches based on individual pharmacogenetics 
and pharmacogenomics [Cadman P., O’Connor D., 
2003; Guidelines of ESC/ESH, 2007; Ioannidis J., 
2009; Stavroulakis G. et al., 2000; Sydorchuk L., 
2008; Sydorchuk L. et al., 2008; 2009; 2010]. 
The aim of the present study is evaluation of daily 
blood pressure monitoring (DBPM) data changes in 
patients with essential arterial hypertension (EAH) 
under pharmacogenetically determined treatment 
depending on five genes polymorphism: insertion/
deletion of angiotensin-converting enzyme gene 
(ACE, I/D), the first type receptor of angiotensin II 
gene (AGTR1, A1166C), endothelial NO-synthase 
gene (eNOS, T894G), Peroxisome proliferators-
activated nuclear receptor-γ2 gene, associated with 
insulin resistance (PPAR-γ2, Pro12Ala), β1-adren-
ergic receptor (ADRβ1, Arg389Gly).
MATERIAL AND METHODS
In Prospective Research Study took part 370 
patients with EAH I-III severity stages (WHO, 
1999), in which mean office BP exceeded 140/90 
mm Hg in 7 days after antihypertensive drugs abo-
lition. BP was measured in accordance to European 
Societies of Hypertension and Cardiology Guide-
lines requirements [ESH/ESC, 2007] and 249 per-
sons were included into study after screening 
[Sydorchuk L., 2008]. Among them were: women 
made 48.2%, men – 51.8%, mean age was 50.5±10.4 
years. EAH I stage was recorded in 66 (26.5%) 
patients, EAH ІІ in 114 (45.%), EAH ІІІ in 69 
(27.7%) subjects. The mild BP increase was evalu-
ated in 66 (26.5%) patients, moderate in 105 
(42.2%), severe in 78 (31.3%). In all EAH patients 
of ІІ stage left ventricle hypertrophy (LVH) was 
revealed (evaluated with ECG and Еcho-CG); in 14 
persons transitory proteinuria was recorded, in 2 
patients – slight plasma creatinine increase: 115-
133 µmol/L, in 50 patients – “intimae-media” thick-
ness (IMT) of common carotid arteries (CCA) 
enlarged (evaluated with Doppler-Ultrasound scan-
ning, like >0.9 mm); in 15 persons the co-morbidity 
state was diabetes mellitus type 2 (DM 2). Among 
the EAH ІІІ stage patients (n=69) in 28 persons 
there was Stable Angina of I- II functional class 
(FC), Chronic Heart Failure (CHF) I-II (NYHA) 
with preserved LV systolic function, in 12 persons 
– CHF ІІ (NYHA) was recorded as EAH complica-
tion, not a concomitant state; in 6 persons there was 
Q-myocardial infarction in anamnesis; 14 patients 
had transitory ischemic attacks in anamnesis (TIA); 
3 underwent ischemic stroke; 42 persons had LVH; 
all patients had increased IMT of CCA >0.9 mm or 
an atherosclerotic plaque; in 2 persons mild-to-
moderate plasma creatinine increase 134-150 µmol/l
was recorded; in 21 patients DM 2 was diagnosed. 
Control group included 50 practically healthy per-
sons of comparable age and gender (р>0.05).
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Office systolic/diastolic BP (SBP/DBP) and heart 
rate (HR) were measured in accordance to European 
requirements [Guidelines of ESH/ESC, 2007]. Daily 
(24-hour) BP monitoring (DBPM) was done on the 
portable devices “ABPE-02” (“SOLVAIG”, Ukraine-
France) and “ABPM” (“Meditech”, Hungary) accord-
ing to standard protocol (40-55 daily measuring). 
The DBPM data analysis was performed with appro-
priate software of mentioned devices. In addition, 
patients underwent the basic clinical-instrumental 
inspections: ECG in the 12 leads, Еcho-CG, basic 
clinical and biochemical blood analyses; immune-
enzyme and genetic analysis; ophthalmologist and 
neurologist consultations.
Alleles of polymorphic sites of I/D in ACE gene, 
A1166S in AGTR1 gene, T894G in еNOS gene, 
Pro12Ala in PPAR-γ2 gene, Arg389Gly in ADRβ1 
gene were studied by a selection of genomic DNA 
from the leucocytes of peripheral blood with follow-
ing amplification by polymerase chain reaction 
(PCR) on programme amplificator “Amply” (Mos-
cow, Russia). Alleles Discrimination of AGTR1, 
eNOS, PPAR-γ2 and ADRβ1 genes performed with 
restriction enzymes Ddel, BanII, CseI and FaqI
accordingly. The amplificated DNA fragments were 
divided by the gel-electrophoresis based method, 
stained with bromine ethidium, visualized with UV-
transluminator in presence of molecular marker lad-
der (100-1000 bp) [Sydorchuk L., 2008].
For elucidation of personal drugs sensitivity we 
conducted a 2-3 weeks empiric antihypertensive 
“sequential” monotherapy trial with the first-line 
drugs, then performed the comprehensive analysis of 
treatment results depending on the analysed genes geno-
type [Sydorchuk L. et al., 2009] and took into account 
the adequate “responder BP rate” (SBP/DBP reduc-
tion ≥20/10 mm Hg), or “target” BP (<140/90 mm Hg)
achievement, in accordance to European recommen-
dations [Guidelines of ESH/ESC, 2007]. Then all 
patients underwent pharmacogenetically determined 
treatment correction depending on ACE I/D gene pol-
ymorphism by setting the fixed-dose of antihyperten-
sive drugs combinations recommended by ESC, ESH 
[Guidelines of ESH/ESC, 2007].
Patients were split by genotypes and treatment 
type into 6 groups: 
• 1st group: I-allele of ACE gene carriers (n=60) 
took Hydrochlorothiazide (HCTZ) and angio-
tensin II receptor blocker (ARB II) Telmisartan; 
• 2nd group: I/D-genotype carriers (n=34) took 
HCTZ+β1-adrenobloker (β1-АB – Metopro-
lol, Nebivolol, Bisoprolol or Atenolol), from 
this group we excluded patients with DM 2 
and metabolic syndrome (MS); 
• 3rd group: I/D-genotype carriers (n=50) took 
HCTZ+ACE-inhibitor (ACEI – Ramipril, 
Enalapril or Perindopril); 
• 4th group: DD-genotype carriers (n=15) took 
calcium channels bloker (CCB – Normodipin, 
Amlodipin-S or Amlodipin) + ARB II; 
• 5th group: DD-genotype carriers (n=15) took 
CCB+β1-АB; 
• 6th group: DD-genotype carriers (n=27) took 
CCB+ACEI. 
The drugs were administered one-two times per 
day at individual doses. Drugs’ doses and reception 
numbers were corrected, at necessity, in a week of 
prescription. The total treatment time duration was 9-
12 months, period of supervision: 24-30 months. Dur-
ing the treatment period, the office BP and HR con-
trol, complaints, therapy efficacy, drugs side effects 
were evaluated. At the beginning and at the end of 
treatment the DBPM and above mentioned complex 
of instrumental-laboratory analysis were conducted. 
Totally, 201 patients finished the study; 48 persons 
“dropped out” during treatment period for different 
reasons (migration, refused the offered treatment, did 
not appear on the repeated inspections and so on).
The treatment efficacy was analyzed according to 
European Guidelines [Guidelines of ESH/ESC, 2007]. 
Therapy was considered primary effective at achieve-
ment of “target” office BP <140/90 mm Hg to the 
end of supervision. Secondary efficiency was esti-
mated with number of patients with “target” office 
BP or adequate BP reduction (SBP and/or DBP ≥20 
and/or 10 mm Hg, accordingly); average daily
BP decrease (BP24) <125-130/80 mm Hg, average 
day BP (BPday) of <130-135/80 mm Hg, average 
night BP (BPnight) <120/70 mm Hg [Guidelines of 
ESH/ESC, 2007].
Statistical processing was conducted with MS 
Excel 2003, Primer of Biostatistics 6.05 and Statis-
tica 7.0 (StatSoft Inc., USA) programs software. 
Data authenticity before/after treatment was calcu-
lated with unpaired/pair Student t-criteria (patients’ 
distribution was near to normal on Kolmogorova-
Smirnova test); quality signs analysed with χ2-crite-
rion (at frequencies less than 5 an exact Fisher-test 
was used), after treatment – Mak-Nimara-criterion. 
Differences were considered reliable at р<0.05.
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RESULTS
The DBPM data in EAH patients before treatment 
depending onanalyzed genes polymorphism shown in 
a table 1. Linear Еcho-CG parameters of LV back 
wall thickness in diastola (LVTd) and intraventricle 
septum thickness in diastola (IVTd) in EAH II-III 
patients exceeded analogical data in EAH I patients 
by 10.6% and 18.0% (р<0.05) and 25.0% and 39.0% 
(0.005=р<0.03) accordingly, reliably differed between 
itself (р<0.05). Left Ventricle Mass in EAH ІІ patients 
was 264.90±20.58 g, in EAH ІІІ – 325.60±27.30 g, 
that was more than in EAH I patients on 24.9% 
(р<0.04) and 53.6% (р=0.005), accordingly, with a 
reliable intergroup difference of 22.9% (р<0.05). 
Combined pharmacogenetically determined treat-
ment with HCTZ+ARB during 9-12 months assisted 
reliable SBP24 and DBP24 reduction in ІІ-genotype 
carriers of ACE gene by 11.0% and 12.7% (р<0.04) 
accordingly, in I/D-genotype carriers – by 12.7% 
(p<0.01). AGTR1 gene analysis demonstrated SBP24
and DBP24 decreasing in АА-genotype patients – by 
15.9% and 23.2% (p<0.05), in AC-genotype patients 
– by 16.3% and 14.3% (p<0.01), in СС-genotype car-
riers – by 18.8% and 16.4% (p<0.01), accordingly. In 
patients with GG-genotype of eNOS gene SBP24 and 
DBP24 reduced by 13.9% and 25.0% (p<0.01), in TG-
genotype carriers – by 14.6% and 16.9% (p<0.01), in 
ТТ-genotype carriers – by 13.5% and 14.1% (p<0.01) 
accordingly. In patients with the AlaAla-genotype of 
PPAR-γ2 gene SBP24 and DBP24 decreased by 13.1% 
and 14.1% (p<0.01), in ProAla-genotype carriers – by 
19.9% and 19.8% (p<0.01), in ProPro-genotype carri-
ers – by 19.3% and 18.7% (р≤0.003), accordingly. 
Under treatment in GlyGly-genotype patients of 
ADRβ1 gene SBP24 and DBP24 diminished by 16.7% 
and 25.0% (p<0.001), in ArgGly-genotype carriers – 
by 16.8% and 19.4% (p<0.01), in ArgArg-genotype 
carriers – by 19.3% and 18.8% (p<0.01), accordingly. 
The reliable declining of average daily pulse BP 
(PBP24) after treatment was in C-allele carriers of 
AGTR1 gene, ProPro-genotype of PPAR-γ2 gene and 
ArgGly-genotype carriers of ADRβ1 gene (р<0.05).
Тable 1.
Daily Blood Pressure Monitoring (DBPM) and Heart Rate (HR) data in patients with essential arterial
hypertension before treatment depending on genes polymorphism of ACE (I/D), AGTR1 (А1166С), 
ADRB1 (Arg389Gly), eNOS (T894G) and PPAR-γ2 (Pro12Ala)
Genes Genotypes, (n=249) % N n/n
SBP24, 
mm Hg
DBP24, 
mm Hg
PBP24, 
mm Hg HR24, b/min
Control group, (n=20) 111.06±4,88 68.33±4.06 42.73±2.18 78.57±3.64
АСЕ
II, (n=50) 20.08% 1 134.60±3.70 р 78.55±3.25 р 47.45±3.05 74.90±1.50
I/D, (n=130) 52.21% 2 141.90±3.57 р 85.81±3.16 р 54.70±3.01 р* 76.93±3.28
DD, (n=69) 27.71% 3 155.64±6.25 р*# 96.70±4.20 р*# 64.90±4.75 р*# 89.55±1.95 р*#
AGTR1
АА, (n=123) 49.40% 1 141.90±8.09р 88.80±5.49 р 48.97±5.03 93.57±4.33 р
АС, (n=96) 38.55% 2 139.80±5.03р 87.68±3.74 р 53.57±3.19 р 73.59±4.66*
СС, (n=30) 12.05% 3 160.62±9,43 р*# 93.30±6.24 р 68.57±2.12 р*# 81.03±7.58
eNOS
GG, (n=94) 37.75% 1 138.80±4.34р 92.50±4.39 р 46.0±5.42 65.80±5.97 р
ТG, (n=134) 53.82% 2 143.0±4.06 р 86.02±4.34 р 55.29±4.89 р 76.60±6.61
TT, (n=21) 8.43% 3 144.50±5.04р 88.97±5.56 р 56.67±4.58 р 79.21±6.17*
PPAR–g2
12Ala, (n=72) 28.92% 1 142.50±5.60р 82.30±2.49 р 57.33±7.85 р 78.25±1.85
Pro12Ala (n=162) 65.06% 2 149.70±6.64р 88.65±4,24 р 58.56±4.61 р 78.02±3,07
Pro12, (n=15) 6.02% 3 161.50±4.32 р*# 90.56±1.98 р 72.24±6.14 р* 76.52±3.17
ADRB1
389Gly, (n=25) 10.0% 1 142.46±5.07р 90.14±2.49 р 52.80±3.72 р 67.75±4.95 р
Arg389Gly, (n=102) 41.0% 2 147.59±5.28р 90.49±2.16 р 57.34±2.50 р 74.93±5.91
Arg389, (n=122) 49.0% 3 153.45±7.0 р 91.25±2.95 р 61.70±9.80 р 83.11±6.05*
Notes: SBP24, DBP24, PBP24 – average daily systolic, diastolic, pulse blood pressure; p – differences compared to control
(0.001<p<0.05); * – differences compared to homozygous patients of each gene (II, AA, GG, 12Ala, 389Gly) p<0.05-0.001; 
# – differences compared to heterozygous patients (I/D, AC, GT, Pro12Ala, Arg389Gly) p<0.05-0.001; n (%) – number
(percentage) of observations; N – groups number of each gene.
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The patients’ treatment with HCTZ+β1-AB 
caused SBP24 and DBP24 decreasing in I/D-genotype 
patients of ACE gene by 11.7% and 13.1% (p<0.02), 
accordingly, that did not differ reliably from therapy 
of analogical patients with HCTZ+ARB II combina-
tion. In АА-genotype carriers of AGTR1 gene SBP24
and DBP24 diminished by 15.4% and 18.9% (р<0.01), 
in AC-genotype carriers – by 9.1% and 13.4% 
(р<0.02), accordingly. The analogical decline of 
SBP24 and DBP24 was found: after eNOS gene analy-
sis – significantly better in ТТ-genotype carriers by 
16.0% and 17.2%, accordingly (р<0.01), after PPAR-
γ2 gene – better in Pro-allele carriers by 17.8% 
(р<0.01) and 17.4% and 16,3% accordingly 
(р<0.001), after ADRβ1 gene – reliably better in 
Arg-allele carriers by 16.0% and 19.1% (р<0.001) 
and 16.6% and 16.8% (р<0.01) accordingly, These 
results did not differ certainly from the results of 
treatment with HCTZ+ARB II combination. The 
reliable reduction of PBP24 under the treatment was 
observed in ТТ-genotype carriers of eNOS gene, 
Pro-allele of PPAR-γ2 gene of and in all genotypes’
carriers of ADRβ1 gene (р<0.05).
Under the treatment with HCTZ+ACEI combina-
tion during 9-12 months SBP24, DBP24 and PBP24
decreased in I/D-genotype carriers of ACE gene by 
11.1%, 12.6% (р<0.02) and 6.5%, accordingly. SBP24 
and DBP24 diminishing was reliable under the therapy 
with HCTZ+ACEI in other genotypes-carriers of ana-
lysed genes, unsignificantly weaker than under 
HCTZ+β1-АB treatment combination, and compara-
ble to HCTZ+ARB II combination (р>0.05). 
Under long-term therapy with CCB+ARB ІІ com-
bination SBP24, DBP24 and PBP24 reduced in DD-geno-
type carriers of ACE gene by 18.3%, 22.0% (р<0.001) 
and 20.5% (р<0.05) accordingly, that differed reliably 
from therapy with HCTZ (р<0.05). SBP24 and DBP24
decreasing was significantly deeper under CCB+ARB 
ІІ treatment combination, and reliably differed from all 
combinations with HCTZ for all genotypes-carriers of 
AGTR1 (р<0.04), eNOS (р<0.03), PPAR-γ2 (р<0.03) 
and ADRβ1 genes (р<0.01).
Combined therapy with CCB+β1-АB during 9-
12 months caused decrease of SBP24, DBP24 and 
PBP24 in DD-genotype carriers of ACE gene by 
18.8%, 23.4% (р<0.001) and 18.4% (р<0.05) accor-
dingly, that was more reliable influence than drugs 
combinations with HCTZ (р<0.05), however did not 
differ from results of CCB+ARB II treatment com-
bination. The analogical picture was observed in 
other analysed genes, where SBP24, DBP24 and PBP24
declining under treatment with CCB+β1-АB was 
stronger than under treatment with HCTZ drugs 
combinations, however, did not differ significantly 
in the genotypes of AGTR1, eNOS, PPAR-γ2 and 
ADRβ1genes. 
The average BP daily data changes under 
CCB+ACEI drugs combinations’ treatment during 
9-12 months caused decline of SBP24, DBP24 and 
PBP24 in DD-genotype carriers of ACE gene by 
17.8%, 22.0% (р<0.001) and 19.2% (р<0.03) accor-
dingly, that was stronger, than under treatment with 
HCTZ drugs’ combinations (р<0.05), but did not 
differ substantially from the therapy with other CCB 
drugs combination. SBP24, DBP24 and PBP24 reduc-
tion were significant under CCB+ACEI treatment 
combination in all genotypes-carriers of AGTR1 
gene (better in СС-genotype patients – by 19.7%, 
18.3% and 23.1%, р<0.02, accordingly), eNOS, 
PPAR-γ2 and ADRβ1 genes, but unreliably differed 
from treatment with HCTZ drugs combinations. 
DBPM data (with average daily, day and night 
BP analysis) after pharmacogenetically combined 
treatment achieved the “threshold” in 154 (76.6%) 
patients (Table 2) that reliably did not differ from 
frequency of “target” office BP achievement – 149 
(74.1%) persons. The type of treatment combina-
tion caused “target” BP24 (with DBPM) achieve-
ment in following rates: after HCTZ+ARB II com-
bination – in 55 (91.7%) patients (better in ІІ-geno-
type carriers of ACE gene (р=0.019), СС-genotype 
of AGTR1 gene (p<0.001), G-allele of eNOS gene 
(p=0.002), Ala-allele of PPAR-γ2 gene and GlyGly-
genotype of ADRβ1 gene (р<0.001); after HCTZ+β1-
AB combination – in 25 (73.,5%) persons (better in 
T-alelle carriers of eNOS gene (р<0.001), AlaAla-
genotype of PPAR-γ2 gene and GlyGly-genotype of 
ADRβ1 gene (р<0.001); after HCTZ+ACEI – in 33 
(66.0%) patients (better in TG-genotype carriers of 
eNOS gene (р=0.016), Ala-allele of PPAR-γ2 gene 
and GlyGly-genotype of ADRβ1 gene (р<0.001); 
after CCB+ARB ІІ combination – in 11 (73.3%) 
persons, without a reliable difference between geno-
types; after CCB+β1-AB – in 11 (73.3%) patients 
(easier in Ala-allele carriers of PPAR-γ2 gene 
(р=0.002); after CCB+ACEI – in 19 (70.4%) patients 
(easier in AlaAla-genotype carriers of PPAR-γ2 
gene (р=0.007). These results did not differ signifi-
cantly from the frequency of “target” BP achieve-
ment (р>0.05).
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Pharmacogenetically combined treatment caused 
growth of patients’ number with daily BP “dipper”
profile to 75.6% vs 65.5% before treatment (р<0.001): 
among СС-genotype carriers of AGTR1 gene by 
13.1% (р=0.005), ТТ-genotype of eNOS gene by 
12.3% (р<0.001), AlaAla- and ProPro-genotypes of 
PPAR-γ2 gene by 20.0% (р<0.001) and 13.75% 
(р=0.047), accordingly; GlyGly-genotype of ADRβ1 
gene by 25.8% (р<0.001). The number of patients 
with daily BP “non-dipper” profile diminished to 
19.9% vs 26.5% before treatment (р<0.01): among 
D-allele carriers of ACE gene by 7.9% (р=0.049) 
and 8.7% (р=0.005), accordingly, СС-genotype of 
AGTR1 gene by 6.7% (р<0.01), T-allele of eNOS 
gene by 7.0% (р=0.035) and 9.8% (р<0.01), accor-
dingly; Ala-allele of PPAR-γ2 gene by 13.3% 
Table 2.
“Target” BP achievement (according to Daily Blood Pressure Monitoring data) in patients with
essential arterial hypertension under pharmacogenetically determined treatment during 9-12 months
depending on AH severities and type of treatment
Drugs combination
“Target”
BP 
(DBPM)
BP (DBPM ) below “threshold”
EAH І, 
n=60 (%)
EAH ІІ, 
n=82 (%)
EAH ІІІ, 
n=59 (%)
Total, 
n (%)
HCTZ+ARB II, n=60 (%)
1BP24 29 (48.3) 20 (33.3) 6 (10.0) 55 (91.7)
2BPd 29 (48.3) 20 (33.3) 6 (10.0) 55 (91.7)
3BPn 29 (48.3) 19 (31.7) 7 (11.7) 55 (91.7)
HCTZ+β1-AB, n=34 (%)
1BP24 10 (29.4) 10 (29.4) 5 (14.7) 25 (73.5)
2BPd 10 (29.4) 9 (26.5) 5 (14.7) 24 (70.6)
3BPn 9 (26.5) 10 (29.4) 5 (14.7) 24 (70.6)
HCTZ+ACEI, n=50 (%)
1BP24 10 (20.0) 15 (30.0) 8 (16.0) 33 (66.0)
2BPd 10 (20.0) 15 (30.0) 8 (16.0) 33 (66.0)
3BPn 9 (18.0) 15  (30.0) 7 (14.0) 31 (62.0)
CCB+ ARB II, n=15 (%)
1BP24 4 (26.7) 4 (26.7) 3 (20.0) 11 (73.3)
2BPd 4 (26.7) 4 (26.7) 3 (20.0) 11(73.3)
3BPn 4  (26.7) 4  (26.7) 3 (20.0) 11 (73.3)
CCB + β1-AB, n=15 (%)
1BP24 3 (20.0) 4 (26.7) 4 (26.7) 11 (73.3)
2BPd 3 (20.0) 5 (33.3) 4 (26.7) 12 (80.0)
3BPn 3 (20.0) 5 (33.3) 5 (33.3) 13 (86.7)
CCB + ACEI, n=27 (%)
1BP24 4 (14.8) 9(33.3) 6 (22.2) 19 (70.4)
2BPd 4(14.8) 9(33.3) 6(22.2) 19 (70.4)
3BPn 4(14.8) 10 (37.0) 6(22.2) 20 (74.1)
Total, n (%)
1BP24 60 (100.0) 62 (75.6) 32 (54.2) 154 (76.6)
2BPd 60 (100.0) 62 (75.6) 32 (54.2) 154 (76.6)
3BPn 58 (96.7) 63 (76.8) 33 (55.9) 154 (76.6)
Notes: 1. “Threshold” BP24 according to DBPM – average daily SBP and DBP <125-130 and 80 mm Hg, accordingly 
[Guidelines of ESH/ESC, 2007].
2. “Threshold” BPd – overage SBP and DBP in day time according to DBPM <130-135 and 85 mm Hg, 
accordingly [Guidelines of ESH/ESC, 2007].
 3. “Threshold” BPn – overage SBP and DBP in night according to DBPM <120 and 70 mm Hg, accordingly
[Guidelines of ESH/ESC, 2007].
4. DBPM – Daily Blood Pressure Monitoring. 
5. HCTZ – hydrochlorothiazide; ARB II – angiotensin II receptor blocker;  β1-АB – β1-adrenergic blocker; 
ACEI – angiotensin converting enzyme inhibitor; CCB – calcium channel blocker. 
6. n (%) –  number (percentage) of observations.
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(р<0.001) and 8.0% (р=0.017), accordingly, and 
among GlyGly-genotype carriers of ADRβ1 gene by 
6.4% (р<0.01). The number of patients with daily 
BP “night-peaker” profile decreased to 4.0% vs 7.2% 
before treatment, р=0.026: significantly only in ТТ-
genotype carriers of eNOS gene (р=0.039).
DISCUSSION
Ideas regarding the efficacy of ACEI administra-
tion in EAH patients depending on I/D polymor-
phism of ACE gene are extremely contradictory. In 
Rotterdam Study a higher death rate (general and 
cardio-vascular) was revealed in EAH patients of 
ACE gene D-allele carriers, but just these patients 
gave the best response to ACEI therapy [Bleumink
G. et al., 2005]. G.A. Stavroulakis and co-workers 
[Stavroulakis G. et al., 2000] also revealed certainly 
deeper SBP and DBP decrease especially in DD-
genotype carriers under Fosinopril administration in 
the dose of 20 mg/day during 6 months. However, 
our results do not conform to some authors upshots, 
which did not reveal the hemodynamics changes 
after treatment with ACEI depending on I/D ACE 
gene polymorphism [Sciarrone M. et al., 2003], or 
someone set more reliable BP decline under treat-
ment with ACEI or ARB II in EAH patients with ІІ-
genotype than in such with DD-genotype (р<0.05) 
[Ohmichi N. et al., 1997; Kurland L. et al., 2001; 
Celuyko V.J., Peleckaya O.V., 2008]. These were 
mostly patients with mild or moderate EAH without 
complications. 
Our results showed better influence of HCTZ on 
SBP and DBP decrease in ІІ-genotype carriers of 
ACE gene with the doubtful sensitiveness in 
patients with DD-genotype that conform to research 
data of M.T. Sciarrone and associates [Sciarrone
M. et al., 2003], but partly agree with prospective 
cross double-blind pharmacogenetic GENERS 
Study results performed in Finland (n=233 men; 
35-60 years old; patients with moderate EAH), 
where no clear dependence was proved on BP 
changes (office and DBPM) depending on poly-
morphism of α-adducin (G460W), AGT (M235T), 
ACE (I/D) and AGTR1 (1166 A/C) genes under 4-
week treatment course with thiazide diuretic HCTZ 
(25 mg), Amlodipine (5 mg), Bisoprolol (5 mg) or 
Losartan (50 mg) [Hiltunen T.P. et al., 2006]. 
In 60% EAH patients administration of β1-АB in 
monotherapy does not cause an adequate antihyper-
tensive response [Mason D. et al., 1999; Humma L., 
Terra S., 2002] that conforms to our results before 
pharmacogenetic correction [Sydorchuk L. et al., 
2009]. D.A. Mason and co-workers [Mason D. et al., 
1999] supposed that one of the reasons of low sensi-
tivities to β1-АB is in genetic polymorphism of β-
adrenergic receptors: Arg389 mutation of ADRβ1 
gene accompanied by greater basal and agonists 
mediated adenylatecyclase activity in comparison 
with Gly-allele carriers. Therefore, probably, EAH 
patients especially with Arg389-allele gave 3 times 
better response (according to DBPM data) under 
treatment with Metoprolol during 4-weeks therapy, 
especially ArgArg-genotype carriers (BP decrease 
was by 13.3±8.4%), than such ones with GlyGly-
genotype (by 4.5±8.2%) accordingly (р=0.018) 
[Karlsson J. et al. , 2004] that conforms to our 
results. These researches did not coincide with the 
results of K.M. O’Shaughnessy and colleagues 
[O’Shaughnessy K. et al., 2000], who did not dis-
cover any connections between BP and myocardial 
sizes diminishing in response to the Atenolol or 
Bisoprolol prescription depending on Arg389Gly 
polymorphism of ADRβ1 gene. We set the reliably 
better answer of D-allele carriers of ACE gene to 
monotherapy with β1-AB that correlates with the 
results of J Karlsson. and associates [Karlsson J. et 
al., 2004]; they explained that with the increase of 
blood/tissue concentration of angiotensin ІІ and, 
accordingly, vegetative nervous system activity rise 
especially in DD-genotype carriers, but hereby DBP 
decline was significantly better in Insertion homozy-
gote-carriers of ACE gene.
Thus, pharmacogenetic approaches in treatment 
of EAH patients enable to individualize treatment, 
promote its efficiency, increase sensitivity, and 
decrease the number of drugs side effects [Cadman P., 
O’Connor D., 2003; Ioannidis J., 2009; Sydorchuk L.P.
et al., 2008; 2010]. 
CONCLUSION
Combined pharmacogenetically determined treat-
ment during 9-12 months caused decrease of ave-
rage daily, day and night BP (DBPM) below “thresh-
old” in 154 (76.6%) patients that did not differ sig-
nificantly from frequency of “target” office BP 
achievement – 149 (74.1%) persons. The number of 
patients with normal BP daily profile “dipper”
increased reliably by 10.1% (р<0.001), with “non-
dipper” and “night-peaker” patients amount dimi-
nishing (р<0.05). 
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Long-term combined therapy caused achieve-
ment of “target” average daily BP24 (DBPM) depen-
ding on types of treatment combination: 
after HCTZ+ARB ІІ – in 55 (91.7%) patients; 
after HCTZ+β1-AB – in 25 (73.,5%) persons; 
after HCTZ+ACEI – in 33 (66.0%) patients; 
after CCB+ARB II – in 11 (73.3%) persons,
without a reliable difference between genotypes; 
after CCB+β1-AB – in 11 (73.3%) patients (easier in 
Ala-allele carriers of PPAR-γ2 gene, р=0.002);
 after CCB+ACEI – in 19 (70.4%) patients (easier in 
AlaAla-genotype carriers of PPAR-γ2 gene, р=0.007). 
For EAH I-allele carriers’ patients of ACE gene
more effective is combination with HCTZ+ ARB ІІ, 
than HCTZ+β1-AB or HCTZ+ACEI – 91.7% vs
66.0 or 73.5%, accordingly (р<0.001), for DD-geno-
type carrier patients more effective are combinations
of CCB+ARB ІІ and CCB+β1-AB than CCB+ACEI
– 73.3% vs 70.4%, accordingly. 
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